Mylan Laboratories
-
{
- All
- News
-
US-Based Gilead Licenses Hepatitis C Drug to Cipla, Ranbaxy, 5 Others
US drug maker Gilead Sciences Inc on Monday said it has licensed its hepatitis C drug to seven companies including Cipla Ltd and Ranbaxy Laboratories Ltd to make it available in 91 developing countries including India.
-
Pharma Sector I Complex Injectables In U.S. Market - Patent Expired, Near-Term Opportunities: Nirmal Bang
Pharma Sector I Complex Injectables In U.S. Market - Patent Expired, Near-Term Opportunities: Nirmal Bang
-
Mylan Labs Gets Nod To Manufacture Remdesivir For COVID-19 Patients
The Drug Controller General of India (DCGI) has granted permission to Mylan laboratories to manufacture and market the anti-viral drug remdesivir for ''restricted emergency use'' on hospitalised COVID-19 patients, a senior government official said on Thursday.
-
Biocon Says U.S. FDA Advisory Committee Favours Nod For Proposed Biosimilar
They are looking forward to seek the final approval from the FDA.
-
Foreign Investment Board Clears Mylan's Rs 4,960 Crore FDI Proposal
Based on the recommendations of FIPB meeting held on July 13, 2015, Mylan Laboratories Ltd's proposal for Rs 4,960 crore FDI has been recommended for approval of CCEA, a Finance Ministry statement said.
-
Government Clears FDI Proposals Worth Rs 10,379 Crore
The investment proposals were approved following the recommendation for the same by the Foreign Investment Promotion Board (FIPB), headed by Finance Secretary Rajiv Mehrishi.
-
Mylan to Acquire Famy Care's Women's Health Business for $800 Million
Mylan Inc will acquire certain businesses of Mumbai-based Famy Care Ltd, a specialty women's health care company, for a total consideration of $800 million (over Rs 4,940 crore).
-
US-Based Gilead Licenses Hepatitis C Drug to Cipla, Ranbaxy, 5 Others
US drug maker Gilead Sciences Inc on Monday said it has licensed its hepatitis C drug to seven companies including Cipla Ltd and Ranbaxy Laboratories Ltd to make it available in 91 developing countries including India.
-
Mylan's Rs 5,168 crore deal to buy Strides unit gets cabinet nod
The acquisition, however, is subject to certain conditions. After the completion of the acquisition process, Mylan has to maintain the investment level in R&D in value terms for five years at absolute quantitative level at the time of induction of FDI, according to sources.
-
Government clears 17 FDI proposals worth Rs 262 crore
The government said on Tuesday that it has cleared 17 foreign direct investment proposals totaling Rs 262.56 crore, including that of Sanofi-Synthelabo (India).
-
Government approves 12 FDI proposals worth over Rs 802 crore
Government today said it has approved 12 foreign direct investment (FDI) proposals, including that of Ratnakar Bank, totaling over Rs 802 crore.
-
US-Based Gilead Licenses Hepatitis C Drug to Cipla, Ranbaxy, 5 Others
US drug maker Gilead Sciences Inc on Monday said it has licensed its hepatitis C drug to seven companies including Cipla Ltd and Ranbaxy Laboratories Ltd to make it available in 91 developing countries including India.
-
Pharma Sector I Complex Injectables In U.S. Market - Patent Expired, Near-Term Opportunities: Nirmal Bang
Pharma Sector I Complex Injectables In U.S. Market - Patent Expired, Near-Term Opportunities: Nirmal Bang
-
Mylan Labs Gets Nod To Manufacture Remdesivir For COVID-19 Patients
The Drug Controller General of India (DCGI) has granted permission to Mylan laboratories to manufacture and market the anti-viral drug remdesivir for ''restricted emergency use'' on hospitalised COVID-19 patients, a senior government official said on Thursday.
-
Biocon Says U.S. FDA Advisory Committee Favours Nod For Proposed Biosimilar
They are looking forward to seek the final approval from the FDA.
-
Foreign Investment Board Clears Mylan's Rs 4,960 Crore FDI Proposal
Based on the recommendations of FIPB meeting held on July 13, 2015, Mylan Laboratories Ltd's proposal for Rs 4,960 crore FDI has been recommended for approval of CCEA, a Finance Ministry statement said.
-
Government Clears FDI Proposals Worth Rs 10,379 Crore
The investment proposals were approved following the recommendation for the same by the Foreign Investment Promotion Board (FIPB), headed by Finance Secretary Rajiv Mehrishi.
-
Mylan to Acquire Famy Care's Women's Health Business for $800 Million
Mylan Inc will acquire certain businesses of Mumbai-based Famy Care Ltd, a specialty women's health care company, for a total consideration of $800 million (over Rs 4,940 crore).
-
US-Based Gilead Licenses Hepatitis C Drug to Cipla, Ranbaxy, 5 Others
US drug maker Gilead Sciences Inc on Monday said it has licensed its hepatitis C drug to seven companies including Cipla Ltd and Ranbaxy Laboratories Ltd to make it available in 91 developing countries including India.
-
Mylan's Rs 5,168 crore deal to buy Strides unit gets cabinet nod
The acquisition, however, is subject to certain conditions. After the completion of the acquisition process, Mylan has to maintain the investment level in R&D in value terms for five years at absolute quantitative level at the time of induction of FDI, according to sources.
-
Government clears 17 FDI proposals worth Rs 262 crore
The government said on Tuesday that it has cleared 17 foreign direct investment proposals totaling Rs 262.56 crore, including that of Sanofi-Synthelabo (India).
-
Government approves 12 FDI proposals worth over Rs 802 crore
Government today said it has approved 12 foreign direct investment (FDI) proposals, including that of Ratnakar Bank, totaling over Rs 802 crore.
